Diligence memo · auto-generated · as of July 2, 2026

Tioga Pharmaceuticals Inc

Tioga Pharmaceuticals Inc looks over-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Tioga Pharmaceuticals Inc operates in Pharmaceuticals, based in SAN DIEGO.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Tioga Pharmaceuticals Inc has raised $24M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $10M on 2012-04-04.

Most recent recorded round closed around 2012-04-04.

Valuation (modeled)modeled

Provath models Tioga Pharmaceuticals Inc at approximately $310M (range $11M–$1.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 1.72× the median modeled value of Series A Pharmaceuticals companies in 2010–2012 (57 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 12 months.

Last raise 14.2 yr ago; this sector typically re-raises about every 13 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 1.1× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 69% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 75% of those peers.

Closest niche peers: Satori Pharmaceuticals Inc, Labrys Biologics, Inc., Telsar Pharma, Inc., Acetylon Pharmaceuticals, Inc., Seldar Pharma, Inc..

Peoplefiled

12 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.